Literature DB >> 23317617

Robotic-assisted retroperitoneoscopic adrenalectomy: making a good procedure even better.

Paxton V Dickson1, Gillian C Alex, Elizabeth G Grubbs, Camilo Jimenez, Jeffrey E Lee, Nancy D Perrier.   

Abstract

Posterior retroperitoneoscopic adrenalectomy (PRA) is a minimally invasive procedure offering several advantages over a transabdominal laparoscopic operation. The three-dimensional optics and articulating instrumentation offered by current robotic surgical technology potentially improve this procedure. Robotic-assisted PRA (RA-PRA) was performed in patients meeting standard criteria for minimally invasive adrenalectomy. We prospectively collected demographic, clinical, perioperative, and pathologic data on patients undergoing RA-PRA. Thirty consecutive RA-PRAs were performed in 28 patients (26 unilateral and 2 bilateral). Indications for adrenalectomy included pheochromocytoma (8), hyperaldosteronism (3), hypercortisolism (8), oligometastases (5), and nonfunctional tumors (6). Mean tumor size was 3.8 ± 1.6 cm. Mean body mass index was 30.7 ± 6.5 kg/m(2). Mean operative time was 154 ± 43 minutes for unilateral total adrenalectomy. Four patients with multiple endocrine neoplasia Type 2A-associated pheochromocytomas underwent cortical-preserving procedures. Three patients experienced perioperative complications (one pneumothorax, one urinary retention, one required postoperative blood transfusion). No patient required conversion to an open procedure. Robotic surgical technology is an excellent complement to retroperitoneoscopic adrenalectomy. The three-dimensional view and ergonomic advantages of a robotic procedure promote better visualization and a more flexible approach to dissection. We believe these features may optimize the ability to maintain a vascularized remnant during minimally invasive cortical-sparing adrenalectomy.

Entities:  

Mesh:

Year:  2013        PMID: 23317617

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  8 in total

1.  Robotic Posterior Retroperitoneal Adrenalectomy: Patient Selection and Long-Term Outcomes.

Authors:  Mehmet Gokceimam; Bora Kahramangil; Serkan Akbulut; Ozgun Erten; Eren Berber
Journal:  Ann Surg Oncol       Date:  2021-05-13       Impact factor: 5.344

2.  Robotic retroperitoneoscopic adrenalectomy: useful modifications of the described posterior approach.

Authors:  Zuliang Feng; Michael P Feng; Jessica W Levine; Carmen C Solórzano
Journal:  J Robot Surg       Date:  2017-01-02

Review 3.  Surgical management of adrenocortical tumours.

Authors:  Barbra S Miller; Gerard M Doherty
Journal:  Nat Rev Endocrinol       Date:  2014-03-18       Impact factor: 43.330

4.  Comparison of posterior retroperitoneal and transabdominal lateral approaches in robotic adrenalectomy: an analysis of 200 cases.

Authors:  Bora Kahramangil; Eren Berber
Journal:  Surg Endosc       Date:  2017-10-19       Impact factor: 4.584

5.  A cost-conscious approach to robotic adrenalectomy.

Authors:  Zuliang Feng; Michael P Feng; David P Feng; Mark J Rice; Carmen C Solórzano
Journal:  J Robot Surg       Date:  2018-01-31

6.  Improving Minimally Invasive Adrenalectomy: Selection of Optimal Approach and Comparison of Outcomes.

Authors:  Terry C Lairmore; Jessica Folek; Cara M Govednik; Samuel K Snyder
Journal:  World J Surg       Date:  2016-07       Impact factor: 3.352

7.  Preliminary experience of the robot-assisted laparoscopic excision of a retroperitoneal mass: A case report.

Authors:  Qin Liu; Xinjing Wang; Baiyong Shen; Liangchao Zhao; Qian Zhan; Shulin Zhao; Chenlei Wen; Xiaxing Deng; Chenghong Peng; Hongwei Li
Journal:  Oncol Lett       Date:  2014-09-12       Impact factor: 2.967

Review 8.  Systematic Review of Surgical Approaches for Adrenal Tumors: Lateral Transperitoneal versus Posterior Retroperitoneal and Laparoscopic versus Robotic Adrenalectomy.

Authors:  Young Jun Chai; Hyungju Kwon; Hyeong Won Yu; Su-Jin Kim; June Young Choi; Kyu Eun Lee; Yeo-Kyu Youn
Journal:  Int J Endocrinol       Date:  2014-12-17       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.